financetom
Business
financetom
/
Business
/
GH Research Shares Soar 90% Pre-Bell After Trial of GH001 to Treat Depression Meets All Endpoints
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GH Research Shares Soar 90% Pre-Bell After Trial of GH001 to Treat Depression Meets All Endpoints
Feb 3, 2025 4:44 AM

07:28 AM EST, 02/03/2025 (MT Newswires) -- GH Research ( GHRS ) shares were soaring over 90% in Monday's premarket session after it said a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.

The biopharmaceutical company also said all secondary endpoints were met and that GH001 was well tolerated with no serious adverse events reported in the double-blind part of the trial.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved